Acceleron Pharma reported $283M in Cash and Equivalent for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Acceleron Pharma XLRN:US $ 283M 6M
Akebia Therapeutics AKBA:US $ 169.29M 76.12M
Alexion Pharmaceuticals ALXN:US $ 2825M 510M
Amgen AMGN:US $ 9145M 1458M
Bayer BAYN:GR € 3148M 859M
Biomarin Pharmaceutical BMRN:US $ 818.9M 342.27M
Bluebird Bio BLUE:US $ 1198.77M 852.14M
Clovis Oncology CLVS:US $ 261M 98M
Dicerna Pharmaceuticals DRNA:US $ 204.28M 6.48M
Eli Lilly And LLY:US $ 2365.1M 666.1M
Exelixis EXEL:US $ 527M 170M
Gilead Sciences GILD:US $ 6746M 3305M
GlaxoSmithKline GSK:LN 8166M 3397M
Johnson & Johnson JNJ:US $ 8485M 6957M
Neurocrine Biosciences NBIX:US $ 415M 228M
Pfizer PFE:US $ 1801M 350M
Ptc Therapeutics PTCT:US $ 158.46M 35.17M
Puma Biotechnology PBYI:US $ 90M 7M
Regeneron Pharmaceuticals REGN:US $ 1992.2M 216M
Ultragenyx Pharmaceutical RARE:US $ 335.64M 37.45M
United Therapeutics UTHR:US $ 685.4M 189.8M
Vertex Pharmaceuticals VRTX:US $ 4831.33M 1237.92M